Immuno-Oncology | Specialty

Future of Bladder Cancer Care to Include Immunotherapy Combos

November 29th 2017

Petros Grivas, MD, shares insight on the value of combining immunotherapy regimens in the treatment of patients with urothelial carcinoma.

Immunotherapy to Have Emerging Role in Squamous Cell Lung Cancer

November 22nd 2017

George R. Blumenschein, MD, discusses the current treatment landscape for patients with squamous cell lung cancer.

Dr. Heinzerling on the Development of New Treatments in Early-Stage Lung Cancer

November 22nd 2017

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.

Durvalumab Data Published in NEJM as FDA Weighs NSCLC Approval

November 21st 2017

The FDA granted a priority review to durvalumab in October for the treatment of patients with stage III, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation.

Expert Discusses Promise of Checkpoint Inhibitors in Ovarian Cancer

November 21st 2017

Jonathan Ledermann, MD, discusses the promise of immunotherapy in ovarian cancer and emphasized the importance of participation in clinical trials.

Dr. Inman on Immunotherapy Combinations in Bladder Cancer

November 21st 2017

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.

Atezolizumab/Bevacizumab Combo Improves PFS for Untreated Advanced NSCLC

November 20th 2017

The addition of atezolizumab to bevacizumab, carboplatin, and paclitaxel delayed progression or death compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.

The Future Role of PARP Inhibition in Ovarian Cancer

November 20th 2017

Combinations With PARP Inhibitors for Ovarian Cancer

November 20th 2017

Ovarian Cancer: Selecting an Appropriate PARP Inhibitor

November 20th 2017

Ovarian Cancer: Treating Through Multiple Progressions

November 20th 2017

Ovarian Cancer: Comparisons Between PARP Inhibitors

November 20th 2017

PARP Inhibitors's Role as Maintenance Therapy in EOC

November 20th 2017

Ovarian Cancer: Optimizing Treatment With Niraparib

November 20th 2017

Treating Ovarian Cancer With Niraparib: The NOVA Trial

November 20th 2017

Platinum-Sensitive Relapsed Ovarian Cancer: Rucaparib

November 20th 2017

Value of Olaparib in BRCA-Mutated Advanced Ovarian Cancer

November 20th 2017

PARP Inhibitors' Impact on Advanced Ovarian Cancer

November 20th 2017

Ovarian Cancer: Considerations for Molecular Testing

November 20th 2017

Ovarian Cancer: Testing for Mutations

November 20th 2017